A prospective pharmacy-based, non-interventional, single-arm, mono-national, multi-center study to investigate the application, effectiveness and safety of Visiodoron Euphrasia comp.® eye ointment in patients with eye inflammation

A prospective pharmacy-based, non-interventional, single-arm, mono-national, multi-center study to investigate the application, effectiveness and safety of Visiodoron Euphrasia comp.® eye ointment in patients with eye inflammation - The EuphAS study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040621

Enrollment

150

Registered

2026-06-16

Start date

2026-07-06

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-severe Conjunctivitis (ICD-10 H10.-) H01.0 H00.0 H00.1

Interventions

Group 1: There are two timepoints when observations regarding Visiodoron Euphrasia comp.® eye ointment are documented (“study visits”, V1 and V2) in an electronic case report form (eCRF), solely by th

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - non-severe, non-complicated inflammatory eye disease

Exclusion criteria

Exclusion criteria: - Patients with a suspected severe or complicated inflammatory eye disease - Patients with a known hypersensitivity to any ingredients listed in the summary of product characteristics - Pregnant or lactating women – unless therapy with the IMP has been advised by a physician, pharmacist, druggist/chemist - Patients that use contact lenses during the treatment period with EuphAS - Patients who are staff of the study site or staff of the Sponsor or Contract Research Organization - Concurrent participation in another clinical study

Design outcomes

Primary

Measure	Time frame
• Evaluation of the EuphAS patient population (assessed at V1 via electronic questionnaire) and application pattern (assessed at V2 via electronic questionnaire) in patients with inflammatory eye diseases • Evaluation of the patient-reported effectiveness (assessed at V1 and V2 via electronic questionnaire) of EuphAS for treating inflammatory eye diseases	—

Secondary

Measure	Time frame
Evaluation of patient-reported tolerability of EuphAS in patients with inflammatory eye diseases (tolerability is assessed at V2 via via electronic questionnaire; ADR reporting via spontaneous reporting system)	—

Countries

Switzerland

Contacts

Public ContactMartin Schnelle

Weleda AG

drcrvec01a01aponis@weleda.de+41 61 705 21 21

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026